Drug Profile

KRLS 017

Alternative Names: KRLS-017

Latest Information Update: 28 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ube Industries
Developer Kirilys Therapeutics; Ube Industries
Class Antineoplastics; Small molecules
Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Solid tumours

Most Recent Events

28 Apr 2026 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
05 Apr 2024 Pharmacokinetics and pharmacodynamics data from preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
23 Mar 2022 KRLS-017 licensed to Kirilys Therapeutics worldwide

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com